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Abstract
Breast cancer and prostate cancer are the most common cancers diagnosed in women and men, respectively, in the UK, and radiotherapy is used extensively in
the treatment of both. In vitro data suggest that tumours in the breast and prostate have unique properties that make a hypofractionated radiotherapy treatment
schedule advantageous in terms of therapeutic index. Many clinical trials of hypofractionated radiotherapy treatment schedules have been completed to
establish the extent to which hypofractionation can improve patient outcome. Here we present a concise description of hypofractionation, the mathematical
description of converting between conventional and hypofractionated schedules, and the motivation for using hypofractionation in the treatment of breast and
prostate cancer. Furthermore, we summarise the results of important recent hypofractionation trials and highlight the limitations of a hypofractionated
treatment regimen.
 2015 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Breast and prostate cancer are the most common can-
cers, accounting for 30 and 25% of cancer diagnoses in
women and men, respectively, in the UK. Efforts to improve
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org/licenses/by/4.0/).breast cancer 5 year survival in England has improved from
52% in 1971e1975 to 85% in 2005e2009, whereas the 5 year
survival in prostate cancer has improved from 31 to 81.4%
over the same time periods. This improved outcome is
largely due to increasing awareness of these diseases, the
National Health Service Breast Cancer Screening Pro-
gramme and stage migration in the diagnosis of prostate
cancers [1]. At the same time, radiotherapy has emerged as
an important treatment modality for both breast and
prostate cancer. This review discusses the risks and poten-
tial beneﬁts of using hypofractionated radiotherapy sched-
ules, which have been hypothesised to improve treatment
outcome owing to the speciﬁc properties of each of these
two cancers.Radiotherapy Treatment, Normal Tissue
Effects and the Linear Quadratic Model
Radical radiotherapy treatment regimens involve
dividing the overall radiation dose into a number of frac-
tions, as this takes advantage of the ﬁve Rs of radiotherapy:is is an open access article under the CC BY license (http://creativecommons.
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of normal tissues, redistribution of cells through the cell
cycle and differences in the intrinsic radiosensitivity of
tumour cells compared with normal tissue cells [2]. A
typical conventional fractionation regimen uses 2 Gy frac-
tions delivered daily ﬁve times a week, up to a total of
60e80 Gy, although this varies across treatment centres,
tumour types and patients [3].
A good therapeutic outcome in radiotherapy comprises
both local control of the tumour and minimal late normal
tissue complications. These can be quantiﬁed using the
tumour control probability (TCP) and normal tissue
complication probability (NTCP) curves [4] (Figure 1). The
separation between the curves gives the size of the thera-
peutic index, which can be altered by shifting either the TCP
or the NTCP curve. As the dose per fraction increases, the
probability of toxic effects in late-responding normal tis-
sues increases disproportionately compared with early
responding normal tissues, which are typically less sensi-
tive to fractionation [4]. The cause of the rise in late-
responding normal tissue toxicity is not yet well under-
stood, but may be due to a number of factors, including cell
death and the production of cytokines [5]. Late-responding
normal tissue toxicity can be further subcategorised into
primary effects due to apoptosis of slowly proliferating cells
and consequential effects due to initially acute damage of
early responding normal tissue. It is primary late-
responding normal tissue toxicity that typically limits
radiotherapy treatment regimens [4].
Fractionation sensitivity can be quantiﬁed using a
parameter known as the a/b ratio from the linear quadratic
model, which is formally deﬁned as the dose at which the
proportion of cell killing due to lethal single-hit injuries
(aD) and the accumulation of sublethal injuries (bD2) are
equal. A small a/b ratio indicates tissue with a large sensi-
tivity to changes in dose per fraction. This low a/b ratio can
result from a number of intrinsic properties of the tissue,
such as a greater capacity to repair DNA damage induced by
radiation and a slow proliferation rate [6]. Hence, typically,
late-responding normal tissues have a smaller a/b ratioFig 1. Sigmoid-shaped curves for tumour control (TCP, left) and
normal tissue complication/damage (NTCP, right) probability. The
dashed lines indicate a 60% TCP and a 5% NTCP for a given dose.
Reprinted from [4] with permission from Macmillan Publishers Ltd.(about 2 Gy) than either tumour tissue or early responding
normal tissues (about 10 Gy) [7].Hypofractionated Radiotherapy
A hypofractionated schedule is one that delivers a dose
larger than 2 Gy per fraction (with a lower overall dose). To
convert between conventional and hypofractionated
schedules, the biologically effective dose (BED) calculation,
deﬁned in equation (1) [8], is used. In this equation, D is the
total dose prescribed and d is the dose per fraction. This
allows clinicians to determine a dose equivalent to the
standard prescribed dose for a new schedule, resulting in
the same biological effect either on the tumour or the dose-
limiting normal tissues.
BED ¼ D
2
641þ d
a=b
3
75 (1)
For example, if a clinician prescribes a total of 60 Gy to be
delivered to a tumour with an a/b ratio of 4 Gy (typical for
breast tumour) in conventional 2 Gy fractions, the BED for
this regimen is 60(1þ2/4)¼ 90 Gy. To deliver the same BED
of 90 Gy in 3 Gy fractions, however, we need only deliver
fractions up to a total dose of 90/(1 þ 3/4) ¼ 51 Gy, which in
3 Gy fractions is only 17 fractions.
An extension to the BED is the equivalent dose in 2 Gy
fractions, EQD2Gy, which is deﬁned by equation (2) [9]. The
EQD2Gy of a 51 Gy in 3 Gy fractions hypofractionated
regimen is 51(3 þ 4)/(2 þ 4) ¼ 59.5Gyz 60 Gy, as expected
from the BED example above.
EQD2Gy ¼
D

dþ a=b


2þ a=b
 (2)
Hypofractionated Radiotherapy in Breast
and Prostate Cancer
Although hyperfractionation, the delivery of multiple
doses smaller than 2 Gy to further spare late normal tissue
effects, is of proven effectiveness in oropharyngeal cancers
[10], hypofractionated schedules are potentially attractive
in the treatment of breast and prostate cancer. The a/b ra-
tios of these tumours are thought to be the same or less
than the surrounding late-reacting normal tissues. Prostate
tumours are estimated to have an a/b ratio of about 1e3 Gy
[11] and breast tumours an a/b ratio of about 4 Gy [12]; this
compares with oropharyngeal cancers and other head and
neck squamous cell carcinomas, with a/b ratios of over 8 Gy
[11]. These low a/b ratios are thought to reﬂect the char-
acteristically slower proliferation rates of breast and pros-
tate tumours compared with other tumour types. As a
consequence of this slower proliferation, these tumours
respond in a similar manner to late-responding normal
K.J. Ray et al. / Clinical Oncology 27 (2015) 420e426422tissue rather than early responding normal tissue [13e15],
thereby removing the rationale for hyperfractionated
schedules. Radiotherapy is usually used in breast cancer in
the adjuvant setting, delivering whole breast irradiation by
external beam radiotherapy after breast-conserving surgery
to a lower dose than radical doses given at other tumour
sites. The purpose of treatment is to eliminate any cancer
cells not removed during surgery. In contrast, irradiation of
the prostate is given to a higher radical dose either by
external beam radiotherapy or brachytherapy [6,12].Table 1
a/b ratios estimated from START-A trial [19]
End point a/b ratio (Gy) 95% conﬁdence interval
Locoregional relapse* 4.0 0.0e8.9
Locoregional relapsey 3.5 1.2e5.7
Breast shrinkage 3.5 0.7e6.4
Breast induration 4 2.3e5.6
Telangiectasia 3.8 1.8e5.7
Breast oedema 4.7 2.4e7.0
* Locoregional relapse a/b START-A results.
y Locoregional relapse a/b from START-A combined with START-
pilot results.Beneﬁts of Hypofractionation in Prostate
and Breast Cancer
The primary beneﬁt of treating breast and prostate
cancer with a hypofractionated regimen is the improved
therapeutic index that can be obtained. Hypofractionation
can achieve this in one of two ways when compared with
the conventional fractionated scheme [6]: (i) dose escala-
tion to increase tumour control while maintaining the same
normal tissue complication probability (i.e. shift the TCP
curve to the left in Figure 1) or (ii) maintaining dose
equivalence in terms of tumour cure probability while
decreasing the normal tissue dose (i.e. shifting the NTCP
curve to the right in Figure 1). Physical methods, such as
intensity-modulated radiotherapy, three-dimensional
conformal radiotherapy and charged particle therapy, have
been used in conventionally fractionated radiotherapy to
decrease the normal tissue dose [6] and their use minimises
the toxicity of hypofractionated radiotherapy.
As well as the therapeutic gain of hypofractionation, a
number of other advantages are conferred in terms of
logistical, patient convenience and resource allocation
considerations [16]. Reduced numbers of fractions will
reduce radiotherapy costs in terms of work-hours and fewer
fractions also results in fewer visits for a patient to the
radiotherapy clinic,which ismore convenient and less costly
[17]. However, these advantages should be considered as
‘added bonuses’ to a hypofractionated schedule: its primary
purpose should be for therapeutic gain. To this end,
numerous clinical trials in breast and prostate cancer have
been conducted. Although the aim of many of these trials
was to show a therapeutic gain from using a hypofractio-
nated schedule, others sought only to show that normal
tissue toxicity is comparable for the conventional and
hypofractionated treatment regimens. Therefore, as long as
a hypofractionated schedule is no more toxic than the con-
ventional schedule, it can be argued that the logistical ad-
vantages are sufﬁcient to warrant clinical implementation.
Hypofractionation in breast cancer radiotherapy entered
clinical trials in the UK in 1986 with the Standardisation of
Breast Radiotherapy pilot trial (START-pilot; n ¼ 1410) and
in Canada in 1993 with the Ontario trial (n ¼ 1234) [18].
These were followed in 1999 with the START-A and START-B
trials [19]. These trials challenged conventional wisdom,
which justiﬁed the rationale for 50 Gy in 25 fractions,
namely that cancers in the breast are less sensitive to
changes in dose per fraction than the dose-limitingsurrounding normal tissues. They then tested the hypoth-
esis that breast tumour tissue and surrounding late-
reacting normal tissue are similarly sensitive to fraction
size. The then-conventional 50 Gy in 25 fractions over 5
weeks was compared with 41.6 Gy or 39 Gy in 13 fractions
over 5 weeks in START-A (n ¼ 2236) and with 40 Gy in 15
fractions over 3 weeks in START-B (n ¼ 2215), the latter
being a dose-fractionation already commonly used in the
UK. Primary end points were locoregional relapse and late
normal tissue effects. The START-pilot and START-A trial
were designed to allow estimation of the a/b ratios of breast
tumour and late-responding normal tissue, and similar a/b
ratios were found for breast tumour using locoregional
relapse as the end point and surrounding normal tissue in
the range 3.5e4.7 Gy [19] (Table 1). Ten year follow-up data
are now available [19] and these found that breast
shrinkage, telangiectasia and breast oedema were signiﬁ-
cantly less frequent with 40 Gy than 50 Gy in START-B, with
no evidence that 40 Gy in 15 fractions was less efﬁcient in
achieving locoregional control. These trials resulted in the
standard breast cancer radiotherapy treatment protocol in
the UK changing to 40 Gy in 15 fractions [19].
The randomised UK FAST trial (2004e2007, n ¼ 915)
went further with its hypofractionation regimen, testing
50 Gy in 25 fractions over 5 weeks against either 30 or
28.5 Gy in ﬁve fractions over 5 weeks [20]. Acute tissue
toxicity effects as well as late tissue effects were measured,
with the primary end point being adverse effects in the
breast. Where the START trials showed that the principle of
hypofractionation in breast cancer treatment was effective,
the FAST trial investigated how much the dose per fraction
could be increased before adverse acute normal tissue re-
actions became intolerably high. After a 3 year median
follow-up, the 28.5 Gy fractionation scheme was compara-
ble with the 50 Gy scheme in terms of adverse reactions,
and lower than the 30 Gy scheme because the total dose to
the tissuewas lower [20]. This trial has been followed by the
FAST Forward trial, which closed 2 years earlier than ex-
pected after very rapidly recruiting 4000 patients. FAST
Forward is testing 40 Gy in 15 fractions over 3weeks against
two accelerated hypofractionation schemes of 26 or 27 Gy
in ﬁve fractions over 5 days. The decreased overall treat-
ment time may improve tumour cure probability by
decreasing the effect of tumour repopulation over the
treatment time, but may also increase early responding
Table 2
Summary of the breast cancer hypofractionation trials mentioned in this review
Trial name Dates No.
patients
Trial arm Control arm a/b estimate
START pilot 1986e1998 1410 39Gy or 42.9Gy, 13 fractions, 5 weeks 50Gy, 25 fractions, 5 weeks 3.5e4.7 Gy*
Ontario 1993e1996 1234 42.5Gy, 16 fractions, 3 weeks 50Gy, 25 fractions, 5 weeks N/A
START-A 1999e2002 2236 39Gy or 41.6Gy, 13 fractions, 5 weeks 50Gy, 25 fractions, 5 weeks 3.5e4.7 Gy*
START-B 1999e2002 2215 40Gy, 15 fractions, 3 weeks 50Gy, 25 fractions, 5 weeks N/A
FAST 2004e2007 915 28.5Gy or 30Gy, 5 fractions, 5 weeks 50Gy, 25 fractions, 5 weeks 2.3e2.6 Gy*
RAPID 2006e2011 2135 38.5Gy, 10 fractions, 5 days (partial breast) 42.5Gy, 16 fractions or 50Gy,
25 fractions daily (whole breast)
N/A
FAST Forward 2011epresent 4000 26Gy or 27Gy, 5 fractions, 5 days 40Gy, 15 fractions, 3 weeks Follow-up
* Range of a/b values calculated depending on end point used, see Table 1.
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gated by the decreased overall dose. The ﬁve-fractions-in-5-
days schedule is hugely convenient to patients, and frees up
large amounts of machine capacity in an era where, with
increasing patient numbers, this is at a premium. Further
hypofractionation may be possible, where a single fraction
delivered to part of the breast is sufﬁcient for tumour con-
trol [21]. The clinical trials referred to in this review are
summarised in Table 2.
The breadth and success of clinical trials of hypofractio-
nation in breast cancer is encouraging; for prostate cancer
the situation is less clear-cut. A recent review of 16 pro-
spective randomised clinical trials comprising a total of
1828 patients concluded that hypofractionation for prostate
cancer should still only be used in a clinical trial setting,
owing to the uncertainties associated with the measure-
ment of the a/b ratio for prostate tumour tissue [3].
Nevertheless, studies have continued, with one phase III
randomised trial in Australia (n ¼ 217) reporting a long-
term therapeutic advantage in terms of biochemical
relapse-free survival and also genitourinary side-effects at 4
years. Here the authors compared hypofractionated radio-
therapy, using 55 Gy in 20 fractions over 4 weeks, to con-
ventional radiotherapy, comprising 64 Gy in 32 fractions
over 6.5 weeks, at a median follow-up of 7.5 years [22]. A
recent meta-analysis of seven trials of 5969 patients, from a
radiobiological perspective, gave an estimate of the a/b ratio
for biochemical relapse-free survival of 1.4 (95% conﬁdence
interval 0.9e2.2) Gy [23], supporting the strategy of hypo-
fractionation in prostate cancer.Table 3
Summary of the prostate cancer hypofractionation trials mentioned in
Trial name Dates No. patients Trial arm
“Australian trial” 1996e2003 217 55Gy, 20 fract
CHHiP 2002e2006 3216 60Gy, 20 fract
19 fractions
PROFIT 2005e2012 1204 60Gy, 20 fract
HYPRO 2006e2011 800 64.6Gy, 19 fra
HYPO-RT-PC 2005epresent 592 42.7Gy, 7 frac
PACE 2012epresent 1700 36.25Gy, 5 fra
4 fractions wiThe Conventional versus Hypofractionated High-dose
intensity-modulated radiotherapy for Prostate cancer
(CHHiP) study (n¼ 3216) between 2002 and 2006 in the UK
compared the standard 74 Gy in 37 fractions over 7.5 weeks
against two hypofractionated schedules: 60 or 57 Gy in 20
or 19 fractions, respectively [24]. Although still in active
follow-up, preliminary analysis of 457 patients using grade
2 toxicity in the bowel or bladder on the Radiation Therapy
Oncology Group (RTOG) scale as an end point seems to
suggest that the hypofractionated schedules are safe and
cause no more early/late normal tissue complications than
the conventional regime 2 years after treatment [24]. The
study design is also such that an estimate of the a/b ratio
should be possible, and with 3216 patients in the trial it is
thought the result will have a narrower 95% conﬁdence
interval than previous estimates. Further clinical trials
either ongoing or in follow-up in Canada (‘PROFIT’, ISRCTN
43853433), the Netherlands (‘HYPRO’, ISRCTN 85138529),
Scandinavia (‘HYPO-RT-PC’, ISRCTN 45905321) and the UK
(‘PACE’, NCT01584258) will also contribute to a further
enhancement in the precision of a/b estimates. These trials
are summarised in Table 3.Risks Associated with Hypofractionation in
Breast and Prostate Cancer
To some extent the hypofractionation approach is less
toxic to normal tissue in breast cancer than in prostate
cancer, as for the former lower relative doses are used in thethis review
Control arm a/b estimate
ions, 4 weeks 64Gy, 32 fractions, 6.5 weeks N/A
ions or 57Gy, 74Gy, 37 fractions, 7.5 weeks Follow-up
ions, 4 weeks 78Gy, 39 fractions, 8 weeks N/A
ctions, 7 weeks 78Gy, 39 fractions, 8 weeks N/A
tions, 3 weeks 78Gy, 39 fractions, 8 weeks N/A
ctions or 38Gy,
th CyberKnife
78Gy, 39 fractions, 8 weeks Recruitment
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peutic ratio when using a hypofractionated schedule is
based on the assumption that the a/b ratio in breast and
prostate cancer is lower than that of the surrounding
normal tissue. Although measurements of a/b have been
carried out using clinical data, these represent population
averages and suffer fromvery large 95% conﬁdence intervals
reﬂecting large inter-patient variability [11,19]. The START-A
breast cancer hypofractionation trial recruited 2236
women, but still yielded notably large 95% conﬁdence in-
tervals (Table 1) [19]. One prostate hypofractionation trial
[11], which used a combination of external beam radio-
therapy with high dose rate brachytherapy delivered in two
or three implants, measured an estimated a/b of 1.2. How-
ever, because only 192 patients were recruited to their trial,
the 95% conﬁdence interval on this value was 0.03e4.1 Gy.
The inter-patient variability of a/b values suggests that not
all patients will beneﬁt from the same hypofractionated
schedule.
Assuming that breast tumour a/b ratio estimates are
correct, there may be a limit to the extent of hypofractio-
nation that can be used safely. For example, patients in the
RAPID trial that underwent hypofractionated treatment
with multiple fractions per day (38.5 Gy in 10 fractions over
a week) suffered from greater normal tissue toxicity than
those in the control arm (42.5 Gy in 16 fractions) [25]. The
increased toxicity could be a result of many factors,
including insufﬁcient time for normal tissue to repair be-
tween fractions and the prescribed dose being delivered to
too large a volume [25]. The FAST Forward trial may help to
elucidate the lower limit of hypofractionation for breast
cancer treatments.
Early prostate hypofractionation trials yielded low a/b
ratios on comparing tumour control rates obtained with
external beamradiotherapyand lowdose rate brachytherapy
[26,27]. However, these trials are limited in their power by
the fact that they compare two therapy modalities as
opposed to two different schedules of the same therapy
modality, as well as the poorer dose conformity available at
the time [6,27]. In fact, theﬁndingsof somerecent trialsusing
modern radiotherapy techniques are actually rejecting the
hypothesis that hypofractionation is beneﬁcial [3]. The lack
of sufﬁcient follow-up time has hindered many modern
prostate cancer hypofractionation trials as they cannot
adequately report on late-responding normal tissue com-
plications, freedom from biochemical failure or morbidity.
Onemulticentre international study, in2003e2007, reported
equivalent late toxicity effects between the hypofractionated
and conventional treatment arms and signiﬁcantly higher
freedom from biochemical failure for the hypofractionated
arm(88%versus76%,P¼0.014), butonlyaftera3year follow-
up [28]. Such equivalence also limits the precision of any
estimations of the a/b ratio, which in turn may also be
dependent on the stage of the prostate tumour [6].
If the a/b ratios are not accurately estimated and doses
selected appropriately, a hypofractionated schedule, as
withall radiotherapy treatments,may increasenormal tissue
complications unnecessarily and potentially induce sec-
ondary cancers. One study comparing the late-respondingnormal tissue complications in prostate cancer radio-
therapy found that, for patients with initial urinary prob-
lems, there was an increased frequency of complications
following a hypofractionated radiotherapy schedule when
comparedwith a conventional schedule [29]. An assumption
is also being made that the linear quadratic model is valid at
the sizes of dose per fraction used in clinical hypofractio-
nated treatments. Although not a major issue in trials
involvingdosesper fractionup to3 Gy, theFASTForward trial
for breast cancer hypofractionation used a dose per fraction
of over 5 Gy. The validity of the linear quadratic model at a
high dose per fraction is yet to be conﬁrmed [6,30e32].
Another factor that has not been considered in many
clinical studies is the heterogeneous nature of tumour tissue
[33].Most tumours have both poorly andwell-differentiated
cells [34]; this heterogeneity leads to a heterogeneous a/b
ratio across the tumour site (poorly differentiated cells have
a higher a/b than well-differentiated cells). Consequently, a
hypofractionated treatment could be sparing poorly differ-
entiated sections of the tumour relative to the nearby organs
at risk. Simulation of this effect showed that treatment ef-
ﬁcacy decreases for a hypofractionated schedule even if
5e10% of the cells in the tumour are poorly differentiated
[33]. The variation in genetic mutations across the tumour
volume also contributes to its heterogeneity; it has previ-
ously been shown that there is as much inter-patient vari-
ability as there is intra-patient variability when considering
the genetic mutations in biopsies of many tumour types
[35]. These geneticmutations affect the ability of DNA repair
pathways to function after radiation damage, hence
affecting the a/b ratio.
Tumour heterogeneity also has implications on the use of
biochemical relapse-free rate as an end point for measuring
successful treatment of prostate cancer, as poorly differen-
tiated cells produce less prostate-speciﬁc antigen thanwell-
differentiated tumour cells [36]. Prostate cancer-speciﬁc
survival or local tumour control and a long follow-up time
period (10e20 years) are more robust end points. Hetero-
geneity of cell oxygenationwithin a tumour is also an issue;
hypofractionation can result in reduced cell killing in hyp-
oxic regions of tumour tissue [37]. Arguably, the importance
of heterogeneity of the a/b ratio in tumour tissue is a factor
that has been underestimated when determining the efﬁ-
cacy of hypofractionation treatment schedules.Discussion
Hypofractionated therapy schemes have obvious logis-
tical and patient convenience advantages for individuals
with breast or prostate cancer. However, although the breast
cancer trial results are encouraging, the therapeutic gain in
prostate cancer is less clear. This difference is mainly due to
the measurement uncertainty of the a/b ratio for prostate
tumour tissue. Although in vitro work with cell lines has
supported a lower tumour a/b than the surrounding normal
tissue for both cases [38,39], these results have not been
conclusively replicated in human studies of prostate cancer.
This variability may reﬂect insufﬁcient follow-up time or
K.J. Ray et al. / Clinical Oncology 27 (2015) 420e426 425patient numbers to report a precise result, suboptimal
choice of end points or the radiotherapy modality used.
Hypofractionation in breast cancer treatment is now the
standard protocol in the UK. The results of further trials
investigating the limits of hypofractionation, such as the
ﬁve-fractions-over-5-days regimen of the FAST Forward
study, are eagerly awaited. Judging by the success of breast
cancer hypofractionation, if we could get to a point where
the a/b ratio for prostate cancer can be measured in vivo in a
reliable manner and shown to be lower than surrounding
organs at risk, hypofractionated therapy will probably have
a beneﬁcial impact for prostate cancer patients.
In order to address the issue of heterogeneity of tumour
tissue, intensity-modulated radiotherapy could be used to
increase the dose delivered to poorly differentiated areas of
the tumour, but this would require in vivo imaging of cell
differentiation. Adaptive radiotherapy, where the dose dis-
tribution is altered during the treatment schedule to ac-
count for changes in patient anatomy, tumour volume or
areas of tumour that respond later in the course of treat-
ment, may be used to provide more personalised and, ul-
timately, more efﬁcacious treatment for each individual
patient [40]. Alternatively, novel agents might be developed
to alter the protein expression of selected parts of the
tumour, thereby rendering it homogeneous in terms of
radiotherapy response. If areas of tumour with a high a/b
could be targeted based on genetic mutations that impair
DNA repair capability, and this capability manipulated to
decrease the a/b ratio, the tumour may respond more
effectively to hypofractionated schedules. Moreover, calcu-
lations of therapeutic gain when using a hypofractionated
schedule should be carried out using a model that accounts
for the presence of hypoxia in tumours so as not to over-
estimate the cell killing, as can occur when using the linear
quadratic model.Future Directions
Future steps in the clinical implementation of hypo-
fractionated schedules will involve the development of
biomarkers tomeasure individual a/b ratios for each patient
and personalise treatment schedules to provide the opti-
mum outcome. Estimates of a/b are currently based on
population studies and variation between patients may
have a signiﬁcant effect on treatment efﬁcacy for in-
dividuals. An ideal situation would be to measure the a/b
ratio in each patient, while factoring in tumour heteroge-
neity, to enable prediction of the response to a particular
treatment regimen, ultimately personalising the radio-
therapy schedule to maximise the therapeutic index for
each patient. This is a complex, and active, area of research.Acknowledgements
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